## HOLX: Hologic, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.7% below STRENGTH zone (4.0-10.0%); PEG 1.65 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.09)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Invesco Ltd. Buys 3,505,828 Shares of Hologic, Inc. $HOLX**
- Source: MarketBeat | 20251205T122304 | Neutral | Relevance: 100%
- Invesco Ltd. significantly increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 72.5% in the second quarter, purchasing an additional 3,505,828 shares. This acquisition brings Invesco's total holdings to 8,340,785 shares, valued at $543,486,000, representing approximately 3.75% of the company. Other institutional investors also adjusted their positions, and Hologic reported strong quarterly earnings, beating analyst estimates.

**2. Lido Advisors LLC Invests $1.27 Million in Hologic, Inc. $HOLX**
- Source: MarketBeat | 20251205T114943 | Somewhat-Bullish | Relevance: 100%
- Lido Advisors LLC has acquired a new stake of 19,413 shares in Hologic, Inc. (NASDAQ:HOLX) valued at approximately $1.27 million in the second quarter. Other institutional investors have also adjusted their holdings in Hologic, with the stock currently having 94.73% institutional ownership. Analysts maintain a consensus "Hold" rating for Hologic with an average price target of $79.67.

**3. Russell Investments Group Ltd. Sells 63,796 Shares of Hologic, Inc. $HOLX**
- Source: MarketBeat | 20251204T033809 | Neutral | Relevance: 100%
- Russell Investments Group Ltd. reduced its stake in Hologic, Inc. by 28.5% in the second quarter, selling 63,796 shares and now holding 159,770 shares valued at $10.41 million. This comes as Hologic beat Q1 earnings estimates with $1.13 EPS and $1.05 billion revenue while insiders, including CEO Stephen P. Macmillan, also made significant share sales. The company currently holds an average analyst "Hold" rating with a target price of $79.67.

**4. Hsbc Holdings PLC Trims Stock Holdings in Hologic, Inc. $HOLX**
- Source: MarketBeat | 20251205T021011 | Neutral | Relevance: 100%
- Hsbc Holdings PLC significantly reduced its stake in Hologic, Inc. by 39.1% during the second quarter, selling over 939,000 shares but still retaining a substantial holding worth approximately $95.6 million. Despite insider selling from the CEO and a director, institutional ownership remains very high at nearly 95%. Hologic recently surpassed quarterly earnings and revenue estimates and holds an average analyst rating of "Hold" with a target price of $79.67.

**5. Panagora Asset Management Inc. Decreases Stake in Hologic, Inc. $HOLX**
- Source: MarketBeat | 20251204T170830 | Neutral | Relevance: 100%
- Panagora Asset Management Inc. significantly reduced its stake in Hologic, Inc. by 26.3% in the second quarter, selling 178,821 shares and ending with 501,821 shares valued at approximately $32.7 million. This comes as institutional investors own nearly 94.73% of the company, while insiders like CEO Stephen P. Macmillan and Director Christiana Stamoulis have also recently sold shares. Analyst sentiment for Hologic on MarketBeat is a "Hold" with a consensus target price of $79.67, despite the company recently beating Q3 earnings and revenue expectations.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Morgan Stanley | $76 | $69 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 15 ($0.00M) |
| Sells | 26 ($6.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-2.2%)
- T. Rowe Price Invest: 9.7% (-10.5%)
- Blackrock Inc.: 8.7% (-2.7%)
- Manufacturers Life I: 4.7% (-5.2%)
- State Street Corpora: 4.5% (-1.2%)

### Key Risks

1. Insider selling cluster: $6.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.65 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (3.8x). Analyst sentiment positive (1 raises, avg +10%). Insider selling cluster ($6.6M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 8 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.6B |
| Beta | 0.70 |
| 52W Range | $51.90 - $75.34 |
| Short Interest | 2.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.65 |
| Forward P/E | 15.0 |
| Current P/E | 16.4 |
| YoY Growth | 9.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.5% to -1.7% (-1.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.7pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.72% (CS: 39) | Neutral |
| RSI_14 | 68.2 | Neutral |
| MACD Histogram | -0.14 | Bearish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 1.039x | Above |
| vs SMA200 | 1.148x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $74.97
- **Stop Loss:** $74.09 (1.2% risk)
- **Target:** $75.85 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 568
- **Position Value:** $42,582.96
- **Portfolio %:** 42.58%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-04 (Est: $1.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.10 | $1.13 | +2.7% |
| 2025Q2 | $1.05 | $1.08 | +2.7% |
| 2025Q1 | $1.02 | $1.03 | +1.4% |
| 2024Q4 | $1.02 | $1.03 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*